A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

Genentech

Status and phase

Completed

Phase 1

Conditions

Healthy Volunteer

Treatments

Drug: Etrolizumab

Device: Prefilled Auto-injector (Rotaject)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02629744

GX29503

Details and patient eligibility

About

This study is a multi-center, single-arm, open-label study in healthy participants to assess the pain, tolerability, injection leakage, safety, and usability of a single self-administered subcutaneous (SC) dose of etrolizumab. Some participants will receive "needle-experience" training using a needle and syringe on Days -7 and -5, and health care professionals (HCPs) will then assess the participant's suitability to self-inject with a prefilled auto-injector (AI). The remainder of participants will be "needle naïve" and will not have previously self-injected. Eligible" needle experienced" and" needle naive" participants will attend an AI training visit at the study site on Day -3 (three days prior to etrolizumab dosing on Day 1). Following training and simulated injections by the participant the HCP will determine if the participant is suitable to proceed to actual etrolizumab dosing. All eligible study participants will self administer a single dose of etrolizumab (by AI) on Day 1 and will be followed up to Day 85 following dosing. Pain, tolerability, safety and usuability will be assessed.

Enrollment

27 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males or females, between 18 and 65 years of age, inclusive
Within body mass index (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m^2), inclusive
In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiograms (ECGs), and vital signs
Females will be non-pregnant, non-lactating, and either postmenopausal (at least 1 year of non therapy induced amenorrhea), surgically sterile (absence of ovaries and/or uterus) for at least 90 days, or agree to remain abstinent or use a highly effective method of contraception for at least 24 weeks after the single dose of study drug
Males will either be sterile or agree to remain abstinent or use a highly effective method of contraception for at least 24 weeks after the single dose of study drug. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration

Exclusion criteria

Participation in any other investigational study drug or biological agent trial (including investigational vaccines) in which receipt of an investigational study drug occurred within 30 days or 5 half-lives or receipt of a biologic agent occurred within 90 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) and during the entire study
Any prior treatment with etrolizumab or other anti integrin agents (including natalizumab, vedolizumab, and efalizumab)
Any prior exposure to immunosuppressive agents (e.g., methotrexate, azathoprine, mercaptopurine)
Use of IV steroids within 30 days prior to Screening;
Chronic nonsteroidal anti inflammatory drug (NSAID)
Use of any prescription medications/products within 14 days prior to Check in (Day -1)
History of demyelinating disease
Neurological conditions or diseases
History of cancer
History of alcoholism or drug addiction within 1 year prior to Check-in (Day -1)
History of active or latent tuberculosis (TB), regardless of treatment history
History of recurrent opportunistic infections, severe disseminated viral infections (e.g., herpes), or any serious opportunistic infection within the last 6 months
Positive for human immunodeficiency virus (HIV) antibody
Any current or recent signs or symptoms of infection
Inability to sense pain (e.g., peripheral neuropathy) and have a history of or have been diagnosed with a chronic pain syndrome